Skip to content
Manifold Bio logo — Organism-scale intelligence, designed in vivo

Manifold Bio

Organism-scale intelligence, designed in vivo

Founded 2020 United States Boston, United States 81 employees Series A Total: $60.40M Biotechnology, Health Care +2

General Information

Company Name Manifold Bio
Founded Year 2020
Location United States Boston, United States
Founders / Decision Makers
Team member
Employees 81
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series A
Business Model B2B, Platform, API
Revenue Model Licensing, Performance Based, Service Fee
Hiring 3 roles posted in the month to 8 Nov 2026
Social

BounceWatch is an independent company data service, not affiliated with Manifold Bio. To contact Manifold Bio, visit manifold.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Manifold Bio compare?

A PDF of Manifold Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Manifold Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Actively Hiring Oct 28, 2026

Hiring for 3 positions in the last 30 days.

Event Participation Oct 26, 2026

Manifold Bio is participating in BIO-Europe to share updates on their discovery engine.

AI Insight

Bounce Watch AI
1 week ago

Manifold Bio is demonstrating significant operational momentum, highlighted by the successful evaluation of over 500,000 AI-designed tissue-targeting binders, validating the advanced capabilities of its discovery platform. This technical progress is reinforced by strong market recognition, including a spot on LinkedIn's Top Startups list, and active industry engagement at BIO-Europe to showcase its discovery engine. These developments suggest the company is actively expanding its platform's impact and pursuing strategic partnerships within the biopharma sector.

Signal Types
Traction Market Recognition Business Development Hiring
Strategic Labels
Platform Validation Industry Engagement Talent Attraction
Next Move: Partnership
·
Impact: 8/10
·
Ideal For: Biotech VCs — Series A/B, AI-driven Drug Discovery Investors

About Manifold Bio

Manifold Bio, founded in 2020, is a cutting-edge platform therapeutics company headquartered in the United States. The company is known for its bold tagline: "Organism-scale intelligence, designed in vivo". It specializes in leveraging biotechnology, healthcare, health and wellness, and pharmaceuticals to create impactful solutions in the pharmaceutical industry.

The company's distinctive approach is embodied in its mDesign engine, which uniquely integrates AI-guided protein design with multiplexed in vivo data generation. This process enables a continuous cycle of design and translation, ultimately aiming to build a 'virtual organism.' Manifold Bio not only advances its internal pipeline but also collaborates with major global pharmaceutical partners to ensure organism-scale biology has a profound clinical impact.

Recently, Manifold Bio secured a $15.00M Series A investment on April 1, 2024, with contributions from notable investors like SK Ventures, Calibrate Ventures, and TQ Ventures. This investment underscores the growing confidence in Manifold Bio's innovative platform and its potential to revolutionize therapeutic development.

Business keywords: AI-guided therapeutics, in vivo discovery platform, protein design, multiplexed data generation, virtual organism development, therapeutics pipeline, pharmaceutical collaboration, organism-scale biology, protein barcoding, measurement-driven design, biotechnology innovation, multiplexed quantitation, drug development, platform therapeutics

Services & Products

AI-powered protein design
In vivo biologics validation
Multiplexed screening experiments
Therapeutic pipeline development
Partner collaborations

Target Customers

Biopharma companies Medical researchers Healthcare institutions Biotechnology partners Academic institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $15.00M 3
SK Ventures, Calibrate Ventures +1
01 Apr 2024
Series A $40.00M 7
Fifty Years, Horizon Ventures +5
01 Jul 2022
Seed $5.40M 4
Fifty Years, Playground Global +2
01 Sep 2020
Round Undisclosed -
01 Apr 2020
Spinout Undisclosed 2
Wyss Institute, Harvard University
01 May 2019

Manifold Bio Alternatives & Competitors

View All Alternatives
Manifold Bio vs

We build generative AI for protein therapeutics.

9 employees
Biotechnology, Pharmaceutical
Manifold Bio vs
Evozyne
Evozyne United States

Evozyne designs novel therapeutic proteins with generative AI to solve immunology’s toughest challen...

Series B
55 employees
Biotechnology, Pharmaceutical
Manifold Bio vs
Frontier Medicines
Frontier Medicines United States

Frontier Medicines is a biopharmaceutical company that “drugs the undruggable” to transform patients...

Series C
80 employees
Biopharma, Biotechnology

FAQ About Manifold Bio

Organism-scale intelligence, designed in vivo
Manifold Bio was founded in 2020.
Manifold Bio is headquartered in Boston, United States.
Manifold Bio operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on AI-guided therapeutics, in vivo discovery platform, protein design and multiplexed data generation. Its customers include Biopharma companies, Medical researchers and Healthcare institutions.
Manifold Bio has a B2B, Platform and API business model. Its revenue comes from Licensing, Performance Based and Service Fee.
Manifold Bio has approximately 81 employees.
Manifold Bio has completed 5 funding rounds, raising a total of $60.40M. The latest funding stage is Series A.
Manifold Bio offers: AI-powered protein design, In vivo biologics validation, Multiplexed screening experiments, Therapeutic pipeline development, Partner collaborations.
Top alternatives and competitors to Manifold Bio include Diffuse Bio, Evozyne, Frontier Medicines, AI Proteins, A-Alpha Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Manifold Bio and Diffuse Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Manifold Bio, https://bouncewatch.com/company/manifold-bio, updated 8 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout